Analysis of Therapeutic Response to Adalimumab in Behçet’s Uveitis by Ultra-Widefield Fluorescein Angiography

Abstract

Purpose: To investigate the role of ultra-widefield fluorescein angiography (UWFA) for monitoring the therapeutic response to adalimumab in patients with Behcet’s uveitis.Methods: Patients with Behcet’s uveitis treated with adalimumab for ≥ 30 weeks were included. The best-corrected visual acuity (BCVA), grading of anterior chamber cell, grading of vitreous haze, and UWFA findings were assessed at baseline, and at 6, 14, and 30 weeks from the start of adalimumab treatment.Results: A total of 32 eyes of 17 patients were included. There were significant decreases in BCVA and UWFA scores at 6, 14, and 30 weeks after adalimumab administration. UWFA scores for vascular and capillary leakage were decreased at 30 weeks (<i>p</i> = 0.032, <i>p</i> = 0.004), while the UWFA scores for disc hyperfluorescence persisted (<i>p</i> = 0.083). Although vascular and capillary leakage at the posterior pole was significantly decreased at 6, 14, and 30 weeks, there was no significant change of the score for peripheral vascular and capillary leakage from baseline to 6 weeks, from 6 to 14 weeks, and from 14 to 30 weeks.Conclusions: UWFA can be used to evaluate the treatment response of adalimumab in Behcet’s uveitis. The vascular leakage pattern varies depending on the location of retinal vessels.